| X | ||||||||||
- Definition The amount of base consideration for sale of all of the Company's assets primarily relating to the Company's operations primarily relating to the manufacturing and production of cell and gene therapies to uBriGene. No definition available.
|
| X | ||||||||||
- Definition Amount contingent amount of $5.0 million less certain severance obligations and payments payable in connection with the transfer of certain contracts related to the transferred assets No definition available.
|
| X | ||||||||||
- Definition Amount of equity securities issued in pursuant to the Asset Purchase Agreement. No definition available.
|
| X | ||||||||||
- Definition The proceeds from issuance of common shares in a registered direct offering. No definition available.
|
| X | ||||||||||
- Definition Cash proceeds from (payments) for offering costs on the issuance of common shares for a registered direct offering. No definition available.
|
| X | ||||||||||
- Definition The period of time after the closing date of Asset Purchase Agreement. No definition available.
|
| X | ||||||||||
- Definition Ratio applied to the conversion of reverse stock split, for example but not limited to, one share converted to two or two shares converted to one. No definition available.
|
| X | ||||||||||
- Definition Offering price per share of warrants. No definition available.
|
| X | ||||||||||
- Definition Represents the discount off of share price for redemption of warrants. No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). No definition available.
|
| X | ||||||||||
- Definition Amount of accumulated undistributed earnings (deficit). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Per share or per unit amount of equity securities issued. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Reduction in the number of shares during the period as a result of a reverse stock split. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|